The TMC Innovation Institute has been tapped by the government to collaborate on illness-detecting technology. Courtesy of TMC

The Texas Medical Center has been identified as a key partner for a national health-focused initiative. TMCx has been selected as one of eight accelerator programs to be a part of the program that focuses on identifying emerging health security threats, according to a release from TMC.

The United States Department of Health and Human Services has provided TMCx a $96,500 to conduct research and provide solutions for two different challenges within mitigating these risks.

"The first is 'pre-symptomatic' detection of illness, or detecting illness in patients and suggesting treatment before they even begin to show symptoms," the release reads. "The second is addressing sepsis, a life-threatening reaction to infection."

Sepsis, which is one of the most costly illnesses hospitals treat, affects 1.7 million patients a year.

HHS' Biomedical Advanced Research and Development Authority, or BARDA, has a new entity called DRIVe, which stands for Division of Research, Innovation, and Ventures. The effort will be lead by the new organization, which comes at a result of the 21st Century Cures Act that was enacted to spur health security within technology.

In July, HHS officials toured the TMC Innovation Institute campus before deciding to work with the accelerator. TMCx is no stranger to the national spotlight. In November, the organization was lauded for its accelerator program with a national award.

The accelerator has announced its eighth cohort of startups this spring. The 21 companies will be focused on digital health. Last cohort, TMCx accelerated 23 companies that raised $73 million by demo day.

In December, Erik Halvorsen, who had lead the Innovation Institute for a few years, abruptly left his position as director. Lance Black, associate director of TMCx, has been named the interim director.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.